Lim B, Potter DA, Salkeni MA, Silverman P, et al. Sapanisertib Plus Exemestane or Fulvestrant in Women with Hormone
Receptor-Positive/HER2-Negative Advanced or Metastatic Breast Cancer. Clin Cancer Res 2021 Apr 5. pii: 1078-0432.CCR-20-4131.
PMID: 33820779